The role of brain corticotropin-releasing factor type 2 (CRF 2 ) receptors in behavioral stress responses remains controversial. Conflicting findings suggest pro-stress, anti-stress or no effects of impeding CRF 2 signaling. Previous studies have used antisauvagine-30 as a selective CRF 2 antagonist. The present study tested the hypotheses that 1) potential anxiolytic-like actions of intracerebroventricular (i.c.v.) administration of antisauvagine-30 also are present in mice lacking CRF 2 receptors and 2) potential anxiolytic-like effects of antisauvagine-30 are not shared by the more selective CRF 2 antagonist astressin 2 -B. Cannulated, male CRF 2 receptor knockout (n = 22) and wildtype littermate mice (n = 21) backcrossed onto a C57BL/6J genetic background were tested in the marble burying, elevated plus-maze, and shock-induced freezing tests following pretreatment (i.c.v.) with vehicle, antisauvagine-30 or astressin 2 -B. Antisauvagine-30 reduced shock-induced freezing equally in wildtype and CRF 2 knockout mice. In contrast, neither astressin 2 -B nor CRF 2 genotype influenced shock-induced freezing. Neither CRF antagonist nor CRF 2 genotype influenced anxiety-like behavior in the plus-maze or marble burying tests. A literature review showed that the typical antisauvagine-30 concentration infused in previous intracranial studies (,1 mM) was 3 orders greater than its IC 50 to block CRF 1 -mediated cAMP responses and 4 orders greater than its binding constants (K d , K i ) for CRF 1 receptors. Thus, increasing, previously used doses of antisauvagine-30 also exert non-CRF 2 -mediated effects, perhaps via CRF 1 . The results do not support the hypothesis that brain CRF 2 receptors tonically promote anxiogenic-like behavior. Utilization of CRF 2 antagonists, such as astressin 2 -B, at doses that are more subtype-selective, can better clarify the significance of brain CRF 2 systems in stress-related behavior.
Introduction
In mammals, the stress-related peptide corticotropin-releasing factor (CRF) and its paralogs urocortins 1, 2, and 3 (Ucn 1, Ucn 2, Ucn 3), activate two CRF receptor subtypes, CRF 1 and CRF 2 , to varying degrees [1] . CRF 1 receptors mediate endocrine, behavioral, and autonomic responses to stress, which has spurred the development of drug-like CRF 1 antagonists [2] . In contrast, the role of brain CRF 2 receptors in stress responses remains controversial. Studies have implicated anti-stress-like actions, pro-stress-like actions, or a lack of involvement of CRF 2 receptors [1] . Part of this uncertainty may reflect that, unlike the case with CRF 1 antagonists [2] , highly selective (.10,000-fold selectivity), small molecule CRF 2 antagonists remain unavailable. Researchers have instead used truncated CRF 2 -preferring (100-1000-fold selectivity) peptide fragments as CRF 2 (astressin 2 -B; [4] ).
Antisauvagine-30 has been described as a selective CRF 2 antagonist in the literature (1530 hits in Google Scholar as of August 2012). Antisauvagine-30 potently displaces radioiodinated CRF-related ligands from HEK293 cell membranes expressing recombinant mCRF 2b (K d = 1.4 nM; [3] , hCRF 2a (K i = 0.8 nM; [5] , or mCRF 2b receptors (K i = 0.41 nM; [6] and has lower affinity for HEK293 membranes expressing CRF 1 receptors. Several findings suggest, however, that antisauvagine-30 may block CRF 1 receptors at doses that have been used in vivo. First, antisauvagine-30 can displace [
125 I]-oCRF from HEK293-rCRF 1 membranes (Ki = 154-166 nM; [3, 6] and [
125 I]-sauvagine from HEK293-hCRF 1 membranes (Ki = 100 nM; [7] ). Similarly, antisauvagine-30 competes with [
125 I]-astressin to bind rat and human uncoupled CRF 1 receptors (Ki = 66 and 170 nM; [7, 8] . Yet, many intracerebroventricular and intracerebral studies have infused antisauvagine-30 at ,4 orders greater concentrations (1-2 mM) (e.g., see Table 1 ). Moreover, in its original characterization, antisauvagine-30 showed ,30% of the rCRF 1 antagonist potency of astressin [3] , a potent CRF 1 antagonist. Accordingly, anti-sauvagine-30 blocks oCRF-induced cAMP accumulation in HEK293-rCRF1 cells [9] and oCRF-induced cAMP responses in human retinoblastoma Y79 cells [10] with IC 50s = 1-2 mM, concentrations 3 orders lower than those that have been injected. The incomplete selectivity of antisauvagine-30 raises concern that some putative anxiolytic/anti-stress-like actions of antisauvagine-30 previously attributed to antagonism of brain CRF 2 receptors may involve a non-CRF 2 target, such as CRF 1 receptors.
Many antibodies [11] and antagonists [12] were subsequently found to have off-target binding or activity when evaluated in knockout (KO) mice. Here, we tested the hypotheses that any potential anxiolytic-like actions of antisauvagine-30 would 1) be present in mice lacking functional CRF 2 receptors, and 2) not be shared by the more selective CRF 2 antagonist astressin 2 -B. [8] . But, astressin 2 -B shows one order less affinity for CRF 1 receptors (Ki.1000 nM and 890 nM, respectively) [7, 8] than does antisavuagine-30 (Ki = 100 nM) [3, 6, 7, 8] .
A secondary goal of the present study was to evaluate the anxiety-related phenotype of CRF 2 KO mice backcrossed to C57BL/6J background. Previous studies that reported an anxiogenic-like phenotype of CRF 2 knockout mice were performed on a hybrid 129SvJ-C57BL/6J genetic background [13, 14] . However, mixed genetic background transgenic mice can lead to spurious or inconsistent results due to the confounding (due to genetic linkage) and interactive influence of mixed genetic background on observed phenotypes [15] . The CRF 2 null mutation was introduced into embryonic stem cells of the 129Sv genetic background. Due to genetic linkage, CRF 2 null mutant mice studied on a hybrid background will overrepresent the 129Sv genetic background as compared to wildtype mice, which will show comparatively more C57BL/6 background [15] . Anxiogenic-like behavior is greater in 129Sv strain mice than in C57BL/ 6 mice, however [16, 17, 18, 19] . As a result, it is not clear whether the previously reported anxiogenic-like CRF 2 KO phenotype is actually due to the null mutation as opposed to linked 129Sv genetic material. Potentially consistent with the latter possibility, no anxiogenic-like phenotype in elevated plus-maze or open field behavior was seen in CRF 2 KO mice backcrossed 3 generations (,87.5%) to a C57BL/6J background (Coste et al., 2000) . Therefore, we here revisit the anxiety-related phenotype of CRF 2 KO mice that were previously reported to show anxiogenic-like behavior on a hybrid background [13] , but now studied after being backcrossed extensively (.99.975%) onto a C57BL/6J background.
Materials and Methods

Ethics Statement
Procedures adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 1996) and Principles of Laboratory Animal Care and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute (protocol #08-0010). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering.
Subjects
Subjects were adult (26.5-32.3 g at study onset), male CRF 2 receptor KO (n = 22; Crhr2 tm1Klee /Crhr2 tm1Klee ; [13] and wildtype littermate mice (n = 21; WT, $12 generations C57BL/6J backcrossing; $99.9755869% consomy) offspring of heterozygote breeding. Mice were group-housed under a reverse 12 h/12 h light/dark cycle in a humidity-(60%) and temperature-controlled (22uC) vivarium with chow (LM-485 Diet 7012, Harlan, Madison, WI) and water available ad libitum. [20] . A 30-gauge obturator maintained patency. Mice recovered $7 days before testing. Cannula placement was inferred from successful gravity injection and from ventricular spread of injected dye in randomly tested mice.
Drugs and injection
Antisauvagine-30 and astressin 2 -B were synthesized using solidphase methodology, purified using HPLC and characterized using capillary zone electrophoresis, HPLC and MS [4] . Peptides were dissolved in 0.56 PBS before testing and kept on ice. For intracerebroventricular (i.c.v.) infusions, the 30-gauge injector extended 1 mm beyond the cannula and was attached to tubing (0.01 i.d., 0.03 o.d. inches) from which 2 ml solution was delivered into the ventricle by gravity over 30 sec. The injector was left in place for 60 sec. The pretreatment intervals, during which the mouse was returned to its home cage were 15 min for the marble burying test and 30 min for the plus-maze and shock-induced freezing tests.
Study design
Mice were tested during the dark phase in the marble burying, elevated plus-maze, and shock-induced freezing tests using a between-subjects design for treatment. The same set of mice were subjects in the 3 tests. Experiments involved a 2 (Genotype: WT vs. KO)63 (Antagonist: vehicle vs. antisauvagine-30 vs. astressin 2 -B) factorial design. The dose of antisauvagine-30 (i.c.v. ,3 nmol, or 10.7 mg) was representative of doses used in previous studies of stress-or anxiety-related endpoints (Table 1) . Astressin 2 -B was administered at the same dose. Tests were spaced by one week, and mice received a given drug treatment no more than twice across the three tests.
Marble burying
For marble burying testing [21] , mice were individually placed in a polycarbonate cage (29618612 cm) containing 20 marbles (1.5 cm diameter) evenly spaced on 5-cm deep bedding. Marbles covered at least two-thirds by bedding, an index of anxiogenic-like behavior, were counted 30 min later. [22] , indicate increased anxiety-like behavior. More total arm entries indicate increased locomotor activity [22] .
Elevated plus-maze
Shock-induced freezing
Mice were placed in a Mouse NIR Video Fear Conditioning System (Med Associates, St. Albans, VT) housed in a soundproofed box, allowed to habituate for 2 min and then exposed to three 1.5 mA, 1-sec footshocks, separated by 20 sec. Freezing, a CRF/CRF 1 -dependent defensive response [23] , was measured automatically from real-time video recordings (30 frames per second) across 15 min using Video Fear Conditioning Software (Med Associates) that distinguishes between subtle movements, such as whisker twitches, tail flicks and freezing behavior.
Statistics
Analysis of variance (ANOVA) was used to evaluate effects of Genotype, Antagonist and their interaction. Fisher's protected least significant difference tests identified pairwise differences. The software used was Systat 12.0 (SPSS, Chicago, IL). Table 3 lists published studies in which antisauvagine-30 was administered site-specifically to discrete brain regions as a CRF 2 antagonist. As can be seen, the concentrations that have been infused locally range from 137-2000 mM, on the order of those given i.c.v. previously (Table 1) 
Results
Discussion
The present study found that i.c.v. infusion of a dose of antisauvagine-30 intermediate to those used in the literature reduced shock-induced freezing in both wild-type and CRF 2 KO mice, unlike the CRF 2 antagonist astressin 2 -B, which did not mitigate shock-induced freezing in either genotype. The present study also found that neither CRF 2 KO nor i.c.v. astressin 2 -B infusion produced anxiolytic-like effects in 3 tests of anxiety-like behavior. Altogether, the results indicate that increasing doses of antisauvagine-30 lose their specificity and can exert non-CRF 2 -mediated effects at doses previously used. The collective results do not support the hypothesis that activation of brain CRF 2 receptors tonically promotes anxiogenic-like behavior.
Antagonism of CRF 1 receptors is a plausible mechanism for the non-CRF 2 mediated anxiolytic-like actions of antisauvagine-30 seen here on shock-induced freezing. The low-moderate CRF 1 binding affinities (,100 nM) of antisauvagine-30 are not shared by the other widely used CRF 2 antagonist, astressin 2 -B (K i .1000 nM and 890 nM, respectively; [7, 8] , which is similarly potent to antisauvagine-30 at binding CRF 2 receptors (e.g., Table 2 . Effects of genotype and CRF antagonist on behavior in the elevated plus-maze and marble burying tests. Table 3 . Intracerebral (IC) site-specific studies of antisauvagine-30 effects on stress-or anxiety-related endpoints. Non-CRF2 Actions of Antisauvagine- Neither CRF 2 KO nor selective CRF 2 antagonism via astressin 2 -B altered behavior in three anxiety models, suggesting that CRF 2 signaling is not a key modulator of anxiety-like behavior under basal conditions. Two previous studies that reported a basal anxiogenic-like phenotype of CRF 2 knockout mice were performed on a hybrid 129SvJ-C57BL/6J genetic background [13, 14] . In contrast, similar to the present results in mice fully backcrossed onto a C57BL/6J background, no significant anxiety-like phenotype was seen in CRF 2 knockout mice backcrossed 3 generations toward a C57BL/6J background [25] . Thus, because 129Sv and C57BL/6J mice differ in anxietylike behavior [16, 17, 18, 19] , genetic background may have interacted with the effect of CRF 2 null mutation on behavioral measures in previous studies [15] . However, these results should not be prematurely concluded to mean that CRF 2 receptors do not modulate anxiety-like behavior. Consistent with an anxiolytic-like action of CRF 2 activation, i.c.v. administration of type 2 urocortins, selective CRF 2 agonists, can produce anxiolytic-like and anti-stress-like behavioral effects [26, 27, 28, 29, 30, 31, 32, 33, 34] . Perhaps CRF 2 receptors are normally quiescent under basal conditions, but are recruited in compensatory opposition to high or more sustained stress, as brought out following stressors or the anxiogenic-like 129Sv genetic background. Consistent with this hypothesis, CRF 2 KO mice previously showed an anxiogeniclike phenotype in the light-dark box test following 30-min immobilization stress, but not under basal conditions (see Fig.  6A in [35] ). Under this view, the stressful aspects of the 3 tests used in the present study (novelty, brief shock) may have been too brief in duration (,5 min), mild in magnitude, or initiated too soon before the behavioral assessment to allow a putative compensatory CRF 2 response to be observed. Finally, it cannot be ruled out that a larger sample size might have led to a statistically significant pvalue. For example, a trend for an anxiogenic-like effect of CRF 2 null mutation, as reported previously [13, 14] , was present in vehicle-treated subjects of the elevated plus-maze that, if considered separately, would have attained significance with a sample size of 16/group (standardized Cohen's d = 20.73).
While antisauvagine-30 exerted non-CRF 2 actions at the tested dose, this does not mean that it is intrinsically nonselective. Lower in vivo doses or concentrations might be shown via a KO control study to be adequately selective for functional studies. Indeed, the finding that a low central dose of antisauvagine-30 (i.c.v., 400 ng) previously produced an anxiogenic-like effect, opposite to those seen with increasing doses of the antagonist (see Table 1 ), is consistent with the interpretation that antisauvagine-30 may lose specificity with increasing doses. The present result with a 3 nmol dose of antisauvagine-30 suggests that many (if not most) previous intracranial administration studies used a dose that can exert non-CRF 2 mediated effects, complicating their interpretation ( Table 1) . Utilization of CRF 2 antagonists at doses validated to be subtype-selective in knockout mice can help further clarify the biological significance of brain CRF 2 systems in stress-related behavior.
